Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.59
-0.06 (-0.32%)
At close: Oct 31, 2024, 4:00 PM
18.60
+0.01 (0.05%)
After-hours: Oct 31, 2024, 6:06 PM EDT
Summit Therapeutics Employees
Summit Therapeutics had 105 employees as of December 31, 2023. The number of employees increased by 28 or 36.36% compared to the previous year.
Employees
105
Change (1Y)
28
Growth (1Y)
36.36%
Revenue / Employee
n/a
Profits / Employee
-$1,872,648
Market Cap
13.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tenet Healthcare | 106,500 |
Baxter International | 60,000 |
Quest Diagnostics | 48,000 |
Align Technology | 21,610 |
Molina Healthcare | 18,000 |
Avantor | 7,570 |
Hologic | 6,990 |
Natera | 3,293 |
SMMT News
- 1 day ago - Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - Business Wire
- 8 days ago - Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 - Business Wire
- 27 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track - Investopedia
- 4 weeks ago - Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Business Wire
- 6 weeks ago - Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial - Seeking Alpha
- 6 weeks ago - Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 - Business Wire